Two Cancer Companies Close Series A Rounds Netting $144 Million

Cancer companies Delfi Diagnostics and Elucida Oncology announced Series A raises worth $144 million so far. Delfi, which is developing cell-free DNA-based liquid biopsies enhanced via machine learning technology, closed a $100 million Series A round, led by OrbiMed. Meanwhile, drug conjugate company Elucida raised $44 million in a Series A-1 round, bringing its Series A total to $72 million. Elucida’s investors have not been disclosed.